How This State Is Using a 'Netflix Model' to Treat More People for Hepatitis C

In Louisiana, roughly 39,000 people on Medicaid and in correctional facilities have the disease. Only a minuscule portion were receiving treatment because of the high cost of the drugs.

In Louisiana, roughly 39,000 people on Medicaid and in correctional facilities have the disease. Only a minuscule portion were receiving treatment because of the high cost of the drugs. Shutterstock

 

Connecting state and local government leaders

Louisiana partnered with a pharmaceutical company to provide hepatitis C treatment to Medicaid and incarcerated patients at a fixed cost.

In June, officials in Louisiana unveiled a deal several years in the making: the state would partner with a pharmaceutical company to provide unlimited amounts of hepatitis C drugs to its prison and Medicaid populations over a five-year period. 

Under the terms of the deal, Louisiana will pay roughly $60 million each year, approximately what the state spent on treatments for the infectious disease in the last fiscal year. If costs climb beyond that, Asegua Therapeutics, a subsidiary of pharmaceutical giant Gilead, will continue to provide treatment to infected populations for no additional money.

It’s been called the “Netflix model”—an unlimited supply of product for a fixed price; in this case, medication instead of video streaming—but Rebekah Gee, secretary of the Louisiana Department of Health, prefers the term “modified subscription model.” The goal, she said, is to eradicate the disease in Louisiana.

“As health secretary, I wanted to tackle drug prices, particularly as they impact public health and because hepatitis C is the leading infectious disease killer of our time,” she said. “It kills as much as the next 60 infectious diseases combined, so eliminating it is a meaningful goal.”

The subscription model is crucial to that goal because it removes the biggest barrier between poor people with the disease and effective treatment: high drug prices. Hepatitis C, a viral infection that can cause severe liver damage, is curable with a 12-week course of treatment, but the cost of the drug (from $20,000 to $30,000 per course of treatment) puts it out of reach for thousands of residents and makes it difficult for states on fixed budgets to foot the bill for impoverished populations. 

In Louisiana, roughly 39,000 people on Medicaid and in correctional facilities have the disease. Treating them all would have cost $760 million, Gee said.

To manage the cost of treating the disease, the state had rationed its distribution of drugs, essentially requiring that people get very sick before becoming eligible for treatment. Even with that practice, Louisiana could afford to treat just 3% of the Medicaid population and 1% of people in state correctional facilities afflicted with hepatitis C.

“Price was such a limiting factor and that was unacceptable to me and to our governor, particularly in this nation where we have the most expensive health-care system in the world,” Gee said. “It did not seem acceptable to us that people would be dying of a preventable disease when we have a cure, simply because we could not afford it.”

Gee and Gov. John Bel Edwards explored a host of options to craft the deal, including the invocation of an archaic provision of patent law that allows the government to appropriate certain technologies in urgent matters of national security or public interest.

“The pharmaceutical industry, predictably, was not favorable to that,” she said. “So we brought up other ideas, and one was this modified subscription model.”

It’s not a new concept, Gee noted. A similar model is in place in Australia and the Vaccines for Children initiative in the United States runs on the same basic idea. But the model hadn't been used by a state government. The success of implementing it in Louisiana, Gee said, came from a bipartisan coalition of support along with the voluntary participation of the pharmaceutical industry rather than a regulatory framework.

“For this to happen in an environment that’s not regulatory we needed to come up with a solution that was acceptable to the industry, and this became it,” she said. “Solidifying the dedication to solve this problem certainly helped create pressure on the industry to change, but I think also the fact that this is a competitive market helped.”

There are now at least three companies manufacturing drugs to treat hepatitis C, Gee said. By participating in the subscription model, one company was guaranteed an exclusive deal to provide the drug to Louisiana, ensuring income and, in the future, potential profits (as cases of hepatitis C decline, the state may eventually pay more for fewer courses of treatment).

The first doses were delivered to patients on July 15. Insurance claims lag, so the state does not have exact data on the number of people who have been treated so far, though Gee estimates it’s in the hundreds. Treatment will run through 2024, by which time the state hopes to have treated 80% of both its Medicaid and correctional populations with hepatitis C.

“Our goal within that five-year space is to eliminate the vast majority of cases in our state,” Gee said. “Being able to cure everyone in our correctional system will allow us to have individuals re-enter their communities better able to work, feeling better, able to have a productive life and, frankly, save a ton of money.”

Gee hopes the model can serve as a blueprint for other states. The Centers for Medicare and Medicaid Services does as well, saying in a statement that “Louisiana’s innovative approach to leveraging a subscription model to promote access to hepatitis C therapy is a great example of how states can lead in designing solutions.”

Several other states, including Washington, now have similar deals in place. The model could be particularly effective for treating opioid addiction, especially in the correctional system, Gee said—but its widespread implementation depends largely on how well this deal works in Louisiana.

“A modified subscription model can certainly be used for opioid addiction and for addiction more broadly; for expensive cancer cures for children—really anything where you have cost constraints and the need for something, where companies would be willing to have a capped amount to guarantee access,” she said. “I think there’s a lot of interest in this. I think, also, a lot of eyes are on Louisiana to see if we’re successful.”

Kate Elizabeth Queram is a Staff Correspondent for Route Fifty and is based in Washington, D.C.

NEXT STORY: Obesity Rates Are Highest in These Nine States

X
This website uses cookies to enhance user experience and to analyze performance and traffic on our website. We also share information about your use of our site with our social media, advertising and analytics partners. Learn More / Do Not Sell My Personal Information
Accept Cookies
X
Cookie Preferences Cookie List

Do Not Sell My Personal Information

When you visit our website, we store cookies on your browser to collect information. The information collected might relate to you, your preferences or your device, and is mostly used to make the site work as you expect it to and to provide a more personalized web experience. However, you can choose not to allow certain types of cookies, which may impact your experience of the site and the services we are able to offer. Click on the different category headings to find out more and change our default settings according to your preference. You cannot opt-out of our First Party Strictly Necessary Cookies as they are deployed in order to ensure the proper functioning of our website (such as prompting the cookie banner and remembering your settings, to log into your account, to redirect you when you log out, etc.). For more information about the First and Third Party Cookies used please follow this link.

Allow All Cookies

Manage Consent Preferences

Strictly Necessary Cookies - Always Active

We do not allow you to opt-out of our certain cookies, as they are necessary to ensure the proper functioning of our website (such as prompting our cookie banner and remembering your privacy choices) and/or to monitor site performance. These cookies are not used in a way that constitutes a “sale” of your data under the CCPA. You can set your browser to block or alert you about these cookies, but some parts of the site will not work as intended if you do so. You can usually find these settings in the Options or Preferences menu of your browser. Visit www.allaboutcookies.org to learn more.

Sale of Personal Data, Targeting & Social Media Cookies

Under the California Consumer Privacy Act, you have the right to opt-out of the sale of your personal information to third parties. These cookies collect information for analytics and to personalize your experience with targeted ads. You may exercise your right to opt out of the sale of personal information by using this toggle switch. If you opt out we will not be able to offer you personalised ads and will not hand over your personal information to any third parties. Additionally, you may contact our legal department for further clarification about your rights as a California consumer by using this Exercise My Rights link

If you have enabled privacy controls on your browser (such as a plugin), we have to take that as a valid request to opt-out. Therefore we would not be able to track your activity through the web. This may affect our ability to personalize ads according to your preferences.

Targeting cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.

Social media cookies are set by a range of social media services that we have added to the site to enable you to share our content with your friends and networks. They are capable of tracking your browser across other sites and building up a profile of your interests. This may impact the content and messages you see on other websites you visit. If you do not allow these cookies you may not be able to use or see these sharing tools.

If you want to opt out of all of our lead reports and lists, please submit a privacy request at our Do Not Sell page.

Save Settings
Cookie Preferences Cookie List

Cookie List

A cookie is a small piece of data (text file) that a website – when visited by a user – asks your browser to store on your device in order to remember information about you, such as your language preference or login information. Those cookies are set by us and called first-party cookies. We also use third-party cookies – which are cookies from a domain different than the domain of the website you are visiting – for our advertising and marketing efforts. More specifically, we use cookies and other tracking technologies for the following purposes:

Strictly Necessary Cookies

We do not allow you to opt-out of our certain cookies, as they are necessary to ensure the proper functioning of our website (such as prompting our cookie banner and remembering your privacy choices) and/or to monitor site performance. These cookies are not used in a way that constitutes a “sale” of your data under the CCPA. You can set your browser to block or alert you about these cookies, but some parts of the site will not work as intended if you do so. You can usually find these settings in the Options or Preferences menu of your browser. Visit www.allaboutcookies.org to learn more.

Functional Cookies

We do not allow you to opt-out of our certain cookies, as they are necessary to ensure the proper functioning of our website (such as prompting our cookie banner and remembering your privacy choices) and/or to monitor site performance. These cookies are not used in a way that constitutes a “sale” of your data under the CCPA. You can set your browser to block or alert you about these cookies, but some parts of the site will not work as intended if you do so. You can usually find these settings in the Options or Preferences menu of your browser. Visit www.allaboutcookies.org to learn more.

Performance Cookies

We do not allow you to opt-out of our certain cookies, as they are necessary to ensure the proper functioning of our website (such as prompting our cookie banner and remembering your privacy choices) and/or to monitor site performance. These cookies are not used in a way that constitutes a “sale” of your data under the CCPA. You can set your browser to block or alert you about these cookies, but some parts of the site will not work as intended if you do so. You can usually find these settings in the Options or Preferences menu of your browser. Visit www.allaboutcookies.org to learn more.

Sale of Personal Data

We also use cookies to personalize your experience on our websites, including by determining the most relevant content and advertisements to show you, and to monitor site traffic and performance, so that we may improve our websites and your experience. You may opt out of our use of such cookies (and the associated “sale” of your Personal Information) by using this toggle switch. You will still see some advertising, regardless of your selection. Because we do not track you across different devices, browsers and GEMG properties, your selection will take effect only on this browser, this device and this website.

Social Media Cookies

We also use cookies to personalize your experience on our websites, including by determining the most relevant content and advertisements to show you, and to monitor site traffic and performance, so that we may improve our websites and your experience. You may opt out of our use of such cookies (and the associated “sale” of your Personal Information) by using this toggle switch. You will still see some advertising, regardless of your selection. Because we do not track you across different devices, browsers and GEMG properties, your selection will take effect only on this browser, this device and this website.

Targeting Cookies

We also use cookies to personalize your experience on our websites, including by determining the most relevant content and advertisements to show you, and to monitor site traffic and performance, so that we may improve our websites and your experience. You may opt out of our use of such cookies (and the associated “sale” of your Personal Information) by using this toggle switch. You will still see some advertising, regardless of your selection. Because we do not track you across different devices, browsers and GEMG properties, your selection will take effect only on this browser, this device and this website.